Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2014 / Cilt: 48 - Sayı: 2

Psoriasis and metabolic syndrome

Psoriasis ve metabolik sendrom

Pages
95–99
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: In our study, metabolic syndrome was present in 62% patients with psoriasis, compared with 24% of the controls (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background and Design: Psoriasis is a chronic, inflammatory disease that occurs with polygenic and other triggering factors.
📊
Key Findings & Data:Materials and Methods: In this study, we compared the levels of fasting blood glucose, serum lipid (total cholesterol, HDL cholesterol, triglyceride), basal insulin, insulin resistance and body mass index as well as cigarette and alcohol consumption in 50 adult patients with those in 50 age- and gender-matched non-psoriatic controls.
💡
Conclusion & Impact:Results: In our study, metabolic syndrome was present in 62% patients with psoriasis, compared with 24% of the controls (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background and Design: Psoriasis is a chronic, inflammatory disease that occurs with polygenic and other triggering factors. The association of psoriasis, which is considered to be a systemic disease, with other diseases, such as cardiovascular diseases, hepatosteatosis, obesity, diabetes mellitus, hypertension, and hyperlipidemia has been shown. Materials and Methods: In this study, we compared the levels of fasting blood glucose, serum lipid (total cholesterol, HDL cholesterol, triglyceride), basal insulin, insulin resistance and body mass index as well as cigarette and alcohol consumption in 50 adult patients with those in 50 age- and gender-matched non-psoriatic controls. Results: In our study, metabolic syndrome was present in 62% patients with psoriasis, compared with 24% of the controls (p

Özet

Amaç: Psoriasis, poligenik faktörler ve tetikleyici etkenler zemininde ortaya çıkan kronik, inflamatuvar bir deri hastalığıdır. Günümüzde sistemik bir hastalık olarak kabul gören psoriasisin başka hastalıklarla da ilişkisi kanıtlanmıştır. Kardiyovasküler hastalıklar, karaciğer yağlanması, obezite, diyabetes mellitus, hipertansiyon ve hiperlipidemi bu hastalıkların başlıcalarıdır. Gereç ve Yöntem: Bu çalışmada 50 yetişkin psoriasis olgusunun açlık kan glukozları, serum lipid değerleri (total kolesterol, HDL kolesterol, LDL kolesterol, trigliserid), bazal insülin değerleri, insülin dirençleri ve vücut kitle indeksleri, sigara ve alkol alışkanlıkları, yaş-cinsiyet eşleştirmeli 50 non-psoriatik kontrol olgu grubu ile karşılaştırılmıştır. Bulgular: Çalışmamızda psoriatik olguların %62'sinde metabolik sendrom saptanırken bu oran non-psoriatik kontrol grubunda %24dü ve aralarındaki fark istatistiksel olarak anlamlı bulundu. Hasta grubunda metabolik sendromu olanların medyan PAŞİ değeri 13,6 iken, metabolik sendromu olmayanların medyan PAŞİ değeri 11,2 idi ve fark istatistiksel olarak anlamlı bulundu. Sonuç: Çalışmamızda psoriasis olgularında metabolik sendrom ve komponentleri olan diyabetes mellitus, obezite, hipertansiyon, dislipidemi kontrol grubuna kıyasla daha yüksek oranda saptanmıştır. (Türk­derm 2014; 48: 95-9)

🔖

Cite This Article

GÜNAYDIN, A., ÖZDEMİR, F., AYTİMUR, D. (2022). Psoriasis and metabolic syndrome. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 48 - Sayı: 2, 95–99. https://ajindex.com/articles/621821

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Kerkhof VCP, Schalkwijk J: Papulosquamous and eczematous dermatoses Dermatology. Ed. Bolognia JL, Jorizzo JL, Rapini RP. 2. Baskı.
  2. İspanya, Mosby Elsevier 2008;115-135
  3. Gudjonsson EJ, Elder TJ. Psoriasis Fitzpatricks’ Dermatology in general medicine. Ed. Wolff K, Goldsmith AL, Katz IS, Gilchrest AB, Paller SA, Leffell JD. 7. Baskı. Mcgraw-hill company 2008;169-193.
  4. Al-Mutairi N, Al-Farag S, Al-Mutairi A, Al-Shiltawy M: Comorbidities associated with psoriasis: An experience from the Middle East. J Dermatol 2010;37:146-55.
  5. Kim N, Thrash B, Menter A: Comorbidities in psoriasis patients. Semin Cutan Med Surg 2010;29:10-5.
  6. Arslan M, Atmaca A, Ayvaz G, ve ark. Türkiye Endokrinoloji ve Metabolizma Derneği Metabolik Sendrom Kılavuzu 2009.
  7. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE: Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004;53:693-700.
  8. Hanley AJ, Festa A, D’Agostino RB, et al: Metabolic and inflammation variable clusters and predictions of type 2 diabetes: factor analysis using directly measured insülin sensitivity. Diabetes 2004;53:1773-81.
  9. Filizci N, Aydın O, Bozdağ EK: Psoriasis vulgarisli hastalarda lipid profili, lipoprotein-a, apoprotein A ve B düzeylerinin PASI ile korelasyonunun değerlendirilmesi. Türkiye Klinikleri J Dermatol 2005;15:175-9.
  10. Uyanık SB, Arı Z, Onur E, Gündüz K, Tanülkü S, Durkan K: Serum lipids and apolipoproteins in patients with psoriasis. Clin Chem Lab Med 2002;40:65-8.
  11. Pişkin S, Gürkök F, Ekuklu G, Şenol M: Serum lipid levels in psoriasis. Yonsei Med J 2003;44:24-6.
  12. Çelik R, Derviş E, Balaban D, Can G: Psoriasisli hastalarda metabolik sendrom birlikteliği. Türkderm 2010;44:204-8.
  13. Drateln RC, Abundis ME, Munoz BRB, Saldana BR, Ortiz GM: Lipid profile, insulin secretion and insulin sensitivity in psoriasis. Am Acad Dermatol 2003;48:280-4. Christophers E: Comorbidities in psoriasis. Clin Dermatol 2007;25:529-34.
  14. Uçak S, Ekmekçi T, Başat O: Comprassion of various insulin sensitivity indices in psoriatic patients and their relationship with types of psoriasis. J Eur Acad Dermatol Venerol 2006;20:517-22.
  15. Prey S, Bronsard V, Puzenat E, et al: Cardiovascular risk factors in patients with plaque psoriasis.a systemic review of epidemiological studies. J Eur Acad Dermatol Venerol 2010;24:23-30.
  16. Cohen AD, Gilutz H, Henkin Y, et al. Psoriasis and the metabolic syndrome. Acta Derm Venerol 2007;87:506-9.
  17. Davidovici BB, Sattar N, Jörg PC, et al: Psoriasis and systemic inflammatory diseases: potential mechanistic